Ovarian cancer: An update on genetics and therapy

Comprehensive Therapy

Volumn 24, Issue 10, 1998, Pages 477-487

  Penson, Richard T ^a   Shannon, Kristen E ^a   Sharpless, Norman E ^a   Seiden, Michael V ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; TAMOXIFEN; TOPOTECAN;

CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SUSCEPTIBILITY; CLINICAL PROTOCOL; FAMILIAL CANCER; GENE THERAPY; GENETIC SUSCEPTIBILITY; HUMAN; OVARIECTOMY; OVARY CANCER; REVIEW;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0031754558     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics 1997. Cancer. 1997;47:5-27.
2. Scully RE. Ovarian tumors. Am J Pathol. 1977;87:686-720.
3. Cramer DW, Welch WR, Hutchison GB, et al. Dietary animal fat in relation to ovarian cancer risk. Obstet Gynecol. 1984;64:833.
4. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? Lancet. 1983;71:717.
5. Cramer DW, Welch WR. Determinants of ovarian cancer risk II: inferences regarding pathogenesis. J Natl Cancer Inst. 1983;71:717.
6. Cramer DW, Welch WR, Cassells S, et al. Mumps, menarche, menopause and ovarian cancer. Am J Obstet Gynecol. 1983;147:1.
7. Cramer DW, Harlow BL, Titus-Ernstoff L, et al. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998; 35:104-107.
8. Centers for Disease Control. Cancer and steroid hormone study: oral contraceptive and the risk of ovarian cancer. JAMA. 1983;249:1596.
9. Tobacman JK, Greene MH, Tucjer MA, et al. Intra-abdomnal carcinomatosis after prophylactic oophorectomy in ovarian cancer-prone families. Lancet. 1982;2:795.
10. Chen KT, Schooley JL, Flam MS. Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol. 1985;66:93S.
11. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.
12. Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996;14:1545-1551.
13. Sainz de la Cuesta R, Goodman A, Halverson S, Fuller A. En bloc pelvic peritoneal resection of the intraperitoneal pelvic viscera in patients with advanced epithelial ovarian cancer. Cancer J. 1996;2:152-157.
14. Wada H, Enomoto T, Fujita M, et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997;57:5379-5385.
15. Wong LC, Collins RJ, Ngan HS, et al. Etoposide combination chemotherapy in refractory ovarian malignant germ cell tumor. Gynecol Oncol. 1990;39:123-126.
16. Malkasian GD Jr, Knapp RC, Lavin P, et al. Preoperative evaluation of serum CA125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988;159:34.
17. Jacobs IJ, Skates S, Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: a prospective cohort study. Brit Med J. 1996;313:1355-1358.
18. Schildkraut JM, Thompson WD. Familial ovarian cancer: a population based case-control study. Am J Epidemiol. 1988; 128:456-466.
19. Parazzini F, et al. The epidemiology of ovarian cancer. Gynecol Oncol. 1991;43:9-23.
20. Amos CI, Struewing JP. Genetic epidemiology of epithelial ovarian cancer. Cancer. 1993;71:566-572.
21. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
22. Narod, SA, et al. Hereditary and familial ovarian cancer in southern Ontario. Cancer. 1994;74:2341-2346.
23. Houlston RS, et al. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet. 1991;55:291-299.
24. Bewtra C, et al. Hereditary ovarian cancer: a clinicopathological study. J Gynecol Pathol. 1992;11:180-187.
25. Lynch HT, Lanspa S, Smyrk T, et al. Hereditary nonpolyposis colorectal cancer [Lynch syndromes I and II]: genetics, pathology, natural history and cancer control, part 1. Cancer Genet Cytogenet. 1991;53:143-160.
26. Stiechen-Gersdorf E, Gallion HH, Ford D, et al. Familial site-specific ovarian cancer is linked to BRCA1 on 17q1221. Am J Hum Genet. 1994;55:87-875.
27. Liede A, Tonin PN, Sun CC, et al. Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet. 1998;75:55-58.
28. Easton DF, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet. 1993;52:678-701.
29. Narod SA, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Am J Hum Genet. 1995; 56:254-264.
30. Narod SA, Ford, D, et al. Genetic heterogeneity of breast ovarian cancer revisited (letter). Am J Hum Genet. 1995;57: 957-958.
31. Gayther SA, MangionJ, Russell P, et al. Variation of risk of breast and ovarian cancer associated with different germline mutation of the BRCA1 gene. Nat Genet. 1997;15:103-105.
32. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997; 336:1125-1130.
33. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71: 677-685.
34. King MC, Rowell S, Love SM. Inherited breast and ovarian cancer: what are the risks? what are the choices? JAMA. 1993;269:1975-1980.
35. NIH Consensus Conference. Ovarian cancer: screening, treatment, and follow-up. JAMA. 1995;273:491-497.
36. Jacobs I, Stabile I, Bridges J, et al. Multimodal approach to screening for ovarian cancer. Lancet. 1988;2:275.
37. Bourne TH, Whitehead MI, Campbell S, et al. Ultrasound screening for familial ovarian cancer. Gynecol Oncol. 1991; 43:92.
38. DePriest PD, Gallion HH, Pavlik EJ, et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol. 1997;65:408-414.
39. Skates SJ, Xu FJ, Yu YH, et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995;76:2004-2010.
40. Woolas RP, Xu FJ, Jacobs IJ, et al. Elevation of multiple serum markers in stage I ovarian cancer. J Natl Cancer Inst. 1993;85:1748-1751.
41. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med. 1994;121:124-132.
42. Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990;75:263.
43. Munoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States. Proc Amer Soc Clin Oncol. 1996;15:748.
44. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072.
45. Guthrie D, Davy MLJ, Phillips PR. Study of 656 patients with "early" ovarian cancer. Gynecol Oncol. 1983;17:363.
46. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med. 1990;322:1021.
47. 32P). Ann Oncol. 1995;6:887-893.
48. Bolis G, Villa A, Guarnerio P, et al. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer. 1996;77:128-131.
49. Heintz AP, Hacker NF, Berek JS, et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol. 1986;67:783.
50. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. J Natl Cancer Inst Monogr. 1975;42:101.
51. Hacker NF, Berek JS, Lagasse LD, et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983;61:413.
52. Omura GA, Bundy BA, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 1989;7:457-465.
53. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 1992;47:159-166.
54. Goodman HM, Harlow BL, Sheets EE, et al. The role of cytoreductive surgery in the management of stage IV epithelial ovarian cancer. Gynecol Oncol. 1992;46:367-371.
55. Young RC. A second look at second-look laparotomy. J Clin Oncol. 1989;5:1311.
56. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
57. Trope C, Kristensen G. Current status of chemotherapy in gynecologic cancer. Semin Oncol. 1997;24:S15-1.
58. Rowinsky E, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004-1014.
59. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989;111:273-279.
60. Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the gynecologic oncology group. J Clin Oncol. 1996;14: 1895-1902.
61. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol. 1997;15: 187-192.
62. Kohn EC, Sarosy GA, Davis P, et al. A phase I/II trial of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer. Gynecol Oncol. 1996;62:181-191.
63. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955.
64. Ozols RF, Vermorken JB. Chemotherapy of advanced ovarian cancer: current status and future directions. Semin Oncol. 1997;24(suppl 2):1-9.
65. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II trial. J Clin Oncol. 1996;14:3056-3061.
66. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ. Phase II study of liposomal doxorubin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15:987-993.
67. Huinink TBW, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193.
68. Safra T, Jeffers S, Groshen S, et al. Doxil (D) in platinum-refractory epithelial ovarian cancer (EOC): results from three consecutive phase I/II studies. Proc Amer Soc Clin Oncol. 1997;16:349a.
69. Stiff PJ, Bayer R, Kerger C, et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol. 1997;15:1309-1317.
70. Legros M, Dauplat J, Fleury J, et al. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol. 1997;15: 1302-1308.
71. Thigpen TJ. Dose intensity in ovarian carcinoma: hold, enough? (editorial). J Clin Oncol. 1997;15:1291-1293.
72. Pujade-Lauraine E, Guastalla JP, Colombo N, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol. 1996;14:343-350.
73. Edwards RP, Gooding W, Lembersky BC, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: 24-hour versus 7-day infusion. J Clin Oncol. 1997;15: 3399-3407.
74. Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993;68:403-406.
75. Barnes MN, Deshane JS, Rosenfeld M, et al. Gene therapy and ovarian cancer: a review. Obstet Gynecol. 1997;89:145-155.